Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy

Cell Mol Neurobiol. 2022 Jul;42(5):1283-1300. doi: 10.1007/s10571-020-01027-6. Epub 2021 Jan 2.


Parkinson's disease (PD) is a neurodegenerative disorder marked primarily by motor symptoms such as rigidity, bradykinesia, postural instability and resting tremor associated with dopaminergic neuronal loss in the Substantia Nigra pars compacta (SNpc) and deficit of dopamine in the basal ganglia. These motor symptoms can be preceded by pre-motor symptoms whose recognition can be useful to apply different strategies to evaluate risk, early diagnosis and prevention of PD progression. Although clinical characteristics of PD are well defined, its pathogenesis is still not completely known, what makes discoveries of therapies capable of curing patients difficult to be reached. Several theories about the cause of idiopathic PD have been investigated and among them, the key role of inflammation, microglia and the inflammasome in the pathogenesis of PD has been considered. In this review, we describe the role and relation of both the inflammasome and microglial activation with the pathogenesis, symptoms, progression and the possibilities for new therapeutic strategies in PD.

Keywords: Glial cell; Inflammasome; Microglia; Neuroinflammation; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Humans
  • Inflammasomes*
  • Inflammation / pathology
  • Microglia / pathology
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Parkinson Disease* / pathology


  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein